(CercleFinance.com) – Eli Lilly announces that in a phase III study, nearly two-thirds of patients with moderate to severe active ulcerative colitis who were treated with mirikizumab achieved statistically higher clinical remission rates at 12 weeks compared to patients on placebo.
‘Statistically significant’ improvements were also observed on the main secondary endpoints, including clinical, symptomatic, endoscopic and histological (tissue cellular level), compared to those taking a placebo.
‘Mirikizumab has the potential to significantly reduce inflammation, help people achieve remission and reduce bowel urgency, which is a new patient-centric outcome that has not been studied before in a phase 3 trial for ulcerative colitis,” says Geert D’Haens, lead author of the study and professor of gastroenterology at University Medical Centers Amsterdam.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
